Green tea halts progression of cardiac transthyretin amyloidosis: an observational report |
| |
Authors: | Arnt V Kristen Stephanie Lehrke Sebastian Buss Derliz Mereles Henning Steen Philipp Ehlermann Stefan Hardt Evangelos Giannitsis Rupert Schreiner Uwe Haberkorn Philipp A Schnabel Reinhold P Linke Christoph R?cken Erich E Wanker Thomas J Dengler Klaus Altland Hugo A Katus |
| |
Institution: | Department of Cardiology, Angiology, and Respiratory Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany, Arnt_Kristen@med.uni-heidelberg.de. |
| |
Abstract: | Background Treatment options in patients with amyloidotic transthyretin (ATTR) cardiomyopathy are limited. Epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea (GT), inhibits fibril formation from several amyloidogenic proteins in vitro. Thus, it might also halt progression of TTR amyloidosis. This is a single-center observational report on the effects of GT consumption in patients with ATTR cardiomopathy. Methods 19 patients with ATTR cardiomyopathy were evaluated by standard blood tests, echocardiography, and cardiac MRI (n?=?9) before and after consumption of GT and/or green tea extracts (GTE) for 12?months. Results Five patients were not followed up for reasons of death (n?=?2), discontinuation of GT/GTE consumption (n?=?2), and heart transplantation (n?=?1). After 12?months no increase of left ventricular (LV) wall thickness and LV myocardial mass was observed by echocardiography. In the subgroup of patients evaluated by cardiac MRI a mean decrease of LV myocardial mass (?12.5?%) was detected in all patients. This was accompanied by an increase of mean mitral annular systolic velocity of 9?% in all 14 patients. Total cholesterol (191.9?±?8.9 vs. 172.7?±?9.4?mg/dL; p?0.01) and LDL cholesterol (105.8?±?7.6 vs. 89.5?±?8.0?mg/dL; p?0.01) decreased significantly during the observational period. No serious adverse effects were reported by any of the participants. Conclusions Our observation suggests an inhibitory effect of GT and/or GTE on the progression of cardiac amyloidosis. We propose a randomized placebo-controlled investigation to confirm our observation. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|